Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356457 | 1.00 | KMT2A (0.60) | KMT2AMEN1ALDH1A1LMNATDP1 | |
| SCHEMBL5374184 | 0.89 | CYP1A2 (0.46) | KMT2AMEN1ALDH1A1LMNATDP1 | |
| SCHEMBL5365395 | 0.89 | CYP1A2 (0.46) | KMT2AMEN1ALDH1A1LMNATDP1 | |
| SCHEMBL5365390 | 0.89 | CYP1A2 (0.46) | KMT2AMEN1ALDH1A1LMNATDP1 | |
| SCHEMBL5367570 | 0.89 | KMT2A (0.45) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5359445 | 0.89 | KMT2A (0.45) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5359439 | 0.89 | KMT2A (0.45) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5359944 | 0.87 | ALDH1A1 (0.55) | KMT2AMEN1ALDH1A1LMNATDP1 | |
| SCHEMBL5359940 | 0.87 | ALDH1A1 (0.55) | KMT2AMEN1ALDH1A1LMNATDP1 | |
| SCHEMBL5363218 | 0.87 | KDM4E (0.44) | KMT2AMEN1ALDH1A1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852747-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-02-08 | — | — | US | claimed |
| EP-1317425-B1 | RESORCINOL DERIVATIVES | PFIZER PROD INC (US) | 2004-11-03 | — | — | EP | claimed |
| US-20030180236-A1 | Resorcinol derivatives | PFIZER PRODUCTS, INC. | 2003-09-25 | — | — | US | claimed |
| US-6590105-B2 | For skin lightening or depigmentation; works by inhibiting tyrosinase in humans; kits | WARNER-LAMBERT COMPANY | 2003-07-08 | — | — | US | claimed |
| US-20020114770-A1 | Resorcinol derivatives | PFIZER INC. | 2002-08-22 | — | — | US | claimed |
| US-7282592-B2 | Resorcinol derivatives | WARNER-LAMBERT COMPANY (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070122367-A1 | RESORCINOL DERIVATIVES | PFIZER INC. (US) | 2007-05-31 | — | — | US | disclosed |
| US-7173052-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050282899-A1 | Resorcinol for lightening skin removing color | BRADLEY STUART E | 2005-12-22 | — | — | US | disclosed |
| US-6852747-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1317425-B1 | RESORCINOL DERIVATIVES | PFIZER PROD INC (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20030180236-A1 | Resorcinol derivatives | PFIZER PRODUCTS, INC. | 2003-09-25 | — | — | US | disclosed |
| US-6590105-B2 | For skin lightening or depigmentation; works by inhibiting tyrosinase in humans; kits | WARNER-LAMBERT COMPANY | 2003-07-08 | — | — | US | disclosed |
| US-20020114770-A1 | Resorcinol derivatives | PFIZER INC. | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070122367-A1 | RESORCINOL DERIVATIVES | LRAT, NQO1, ALDH1A2 | KMT2A 2259/4885MEN1 2440/4885ALDH1A1 90/4885 |
| US-20030180236-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | KMT2A 2259/4885MEN1 2440/4885ALDH1A1 90/4885 |
| US-20050282899-A1 | Resorcinol for lightening skin removing color | RBP4, NQO1, ALDH1A2 | KMT2A 771/4885MEN1 3029/4885ALDH1A1 164/4885 |
| US-20020114770-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | KMT2A 2259/4885MEN1 2440/4885ALDH1A1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.